Quest Diagnostics Incorporated (NYSE:DGX) – Stock analysts at SunTrust Banks reduced their Q1 2018 earnings per share estimates for Quest Diagnostics in a report issued on Tuesday. SunTrust Banks analyst D. Macdonald now expects that the medical research company will post earnings of $1.31 per share for the quarter, down from their prior estimate of $1.33. SunTrust Banks has a “Hold” rating and a $105.00 price objective on the stock. SunTrust Banks also issued estimates for Quest Diagnostics’ Q2 2018 earnings at $1.52 EPS, Q4 2018 earnings at $1.44 EPS, FY2018 earnings at $5.80 EPS, Q1 2019 earnings at $1.39 EPS, Q2 2019 earnings at $1.58 EPS, Q3 2019 earnings at $1.59 EPS and FY2019 earnings at $6.08 EPS.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.35 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. The business had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.92 billion. During the same quarter last year, the firm earned $1.37 earnings per share. The business’s revenue for the quarter was up 2.4% on a year-over-year basis.

TRADEMARK VIOLATION WARNING: “Quest Diagnostics Incorporated Forecasted to Earn Q1 2018 Earnings of $1.31 Per Share (DGX)” was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/23/quest-diagnostics-incorporated-forecasted-to-earn-q1-2018-earnings-of-1-31-per-share-dgx.html.

DGX has been the subject of a number of other reports. Wells Fargo & Company started coverage on shares of Quest Diagnostics in a research note on Thursday, October 12th. They set a “market perform” rating and a $88.00 price target for the company. Raymond James Financial, Inc. reaffirmed a “market perform” rating on shares of Quest Diagnostics in a research note on Monday, September 25th. Goldman Sachs Group, Inc. (The) cut shares of Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and dropped their price target for the stock from $121.00 to $113.00 in a research note on Tuesday, October 10th. KeyCorp reaffirmed a “hold” rating on shares of Quest Diagnostics in a research note on Friday, October 27th. Finally, Credit Suisse Group dropped their price target on shares of Quest Diagnostics from $110.00 to $99.00 and set a “neutral” rating for the company in a research note on Thursday, September 28th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $106.18.

Shares of Quest Diagnostics (NYSE:DGX) traded up $0.06 during midday trading on Thursday, hitting $92.52. 1,476,400 shares of the company’s stock were exchanged, compared to its average volume of 993,860. Quest Diagnostics has a fifty-two week low of $86.11 and a fifty-two week high of $112.96. The company has a market capitalization of $12,602.24, a P/E ratio of 16.57, a price-to-earnings-growth ratio of 1.93 and a beta of 0.59. The company has a quick ratio of 1.37, a current ratio of 1.47 and a debt-to-equity ratio of 0.78.

Several hedge funds and other institutional investors have recently modified their holdings of DGX. US Bancorp DE lifted its holdings in shares of Quest Diagnostics by 0.9% during the 2nd quarter. US Bancorp DE now owns 18,065 shares of the medical research company’s stock valued at $2,008,000 after buying an additional 156 shares during the last quarter. Insight Capital Research & Management Inc. purchased a new stake in shares of Quest Diagnostics in the 2nd quarter worth approximately $240,000. Wagner Bowman Management Corp purchased a new stake in shares of Quest Diagnostics in the 2nd quarter worth approximately $200,000. Regentatlantic Capital LLC lifted its position in shares of Quest Diagnostics by 0.6% in the 2nd quarter. Regentatlantic Capital LLC now owns 9,257 shares of the medical research company’s stock worth $1,029,000 after purchasing an additional 56 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in shares of Quest Diagnostics by 12.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 606,397 shares of the medical research company’s stock worth $67,406,000 after purchasing an additional 67,706 shares during the period. Institutional investors own 88.52% of the company’s stock.

In other Quest Diagnostics news, Director Daniel Stanzione sold 3,803 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $108.01, for a total transaction of $410,762.03. Following the sale, the director now directly owns 35,359 shares in the company, valued at approximately $3,819,125.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephen H. Rusckowski sold 53,933 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $108.16, for a total transaction of $5,833,393.28. Following the sale, the chief executive officer now owns 220,049 shares in the company, valued at $23,800,499.84. The disclosure for this sale can be found here. Insiders sold a total of 160,396 shares of company stock worth $17,343,852 over the last three months. 1.75% of the stock is currently owned by corporate insiders.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.